Skip to main content
OpenTrials
Completed

NCT Number: NCT02681614

Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning

This clinical research study tests the Uronav system. Patients with prostate cancer will be asked to take part in this study.

Uronav system is an investigational device that is used on this study to help place markers in the patient. These are called fiducial markers and they are placed in the patient to help plan radiation treatment. Radiation therapy treatment will be planned by the treating physician and will not be experimental or part of this research study.

This study will also test the similarities and differences of biopsy tissue structures and the findings from the intraprostatic MRI (internally guided MRI).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Case Comprehensive Cancer Center

Cleveland, Ohio, 44106-5065, United States

About this study

Study Objectives

Specific Aim 1: Evaluate final pathology post-operatively for histopathology confirmation of multiparametric MRI targets detected during treatment planning. This will be accomplished by using transperineal biopsies obtained prior to interstitial brachytherapy during the procedure, while under anesthetic just prior to the placement of the brachytherapy needles and sources.

Specific Aim 2: Evaluate the ability of the Uronav system in a transperineal setting to guide biopsy needle placement using the electromagnetic guidance system and transperineal ultrasound probe stabilization device and stepper.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must have histopathology confirmed prostate cancer that is Gleason score ≤7(4+3) clinical stage ≤ T2bN0M0 with a Prostate-specific antigen (PSA) below 15 ng/mL.
  • Patients must have MRI findings reporting intraprostatic lesions suspicious for malignancy.
  • Patient must not have had any prior treatment for prostate cancer
  • Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2
  • Subjects must have an International Prostate Symptom Score of ≤ 15.
  • Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

  • Gleason score of ≥ 8(4+4)
  • PSA ≥ 15 ng/mL.
  • Clinical stage >T2b or evidence of nodal
  • Patients who are on anticoagulants or high dose aspirin therapy that cannot be safely stopped for greater than 10 days prior to treatment should be excluded to limit increased risk for urinary obstruction.
  • Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • HIV-positive patients on combination antiretroviral therapy are ineligible because of the unlikely risk of prostate cancer being life threatening in this population.

Treatment and study plan

Uronav guided biopsy

Device

All biopsies will be completed in the outpatient setting in the ambulatory operating room prior to routine prostate brachytherapy under general anesthesia.

Patients will be prepped in a dorsal lithotomy position with insertion of a Foley catheter. The perineum will be shaved as needed, and cleansed with antiseptic solution, and the scrotum will be elevated with a towel roll to expose the perineum.

Other names: Phillips Medical's Uronav

Magnetic Resonance Imaging

Device

An MRI (magnetic resonance imaging) is a scan that uses radio waves and a strong magnetic field to provide images of internal organs and tissues. This is not part of the study but will have been done per standard treatment. An MRI will occur at the screening visit and last visit of the study.

Other names: MRI

Primary outcomes

  1. Number of Participants Who Had Biopsies With True Positives Between Biopsy Tissue and Intraprostatic MRI

    Time frame: Within 15 days of screening

    Number of participants who had biopsies with true positives between biopsy tissue and intraprostatic MRI (sensitivity of the intraprostatic MRI)

  2. Number of Biopsies With True Negatives Between Biopsy Tissue and Intraprostatic MRI

    Time frame: Within 15 days of screening

    Number of biopsies with true negatives between biopsy tissue and intraprostatic MRI (specificity of the intraprostatic MRI)

  3. Number of Biopsies With False Positives Between Biopsy Tissue and Intraprostatic MRI

    Time frame: Within 15 days of screening

    Number of biopsies with false positives between biopsy tissue and intraprostatic MRI (positive predictive values of MRI)

  4. Number of Biopsies With False Negatives Between Biopsy Tissue and Intraprostatic MRI

    Time frame: Within 15 days of screening

    Number of biopsies with false negatives between biopsy tissue and intraprostatic MRI (negative predictive values of MRI)

Secondary outcomes

  1. Number of Participants With Infections Within 30 Days

    Time frame: Up to 30 days post biopsy

    The infection rate within 30 days due to the procedure will be collected for expected acute events and these data will be used for reporting the study results for specific aim 2 evaluation the transperineal use of Uronav to determine if the transperineal biopsy approach results in a reduced rate of infection compared to standard transrectal biopsies .

  2. Number of Hospitalizations Within 30 Days

    Time frame: Up to 30 days post biopsy

    The hospitalization rate within 30 days due to the procedure will be collected for expected acute events and these data will be used for reporting the study results for specific aim 2 evaluation the transperineal use of Uronav to determine if the transperineal biopsy approach results in a reduced rate of hospitalization compared to standard transrectal biopsies .

  3. Number of Participants Who Had Successful Completion of Transperineal Biopsy Procedure

    Time frame: Up to 15 days after screening

    The study will be to report the incidence of successful completion of the transperineal biopsy procedure using the Uronav system which is provided by Philips Medical as part of the support for this study

  4. Dosimetric Coverage of Brachytherapy Implant Described by Mean V100 (% Volume)

    Time frame: Up to 15 days after screening

    Post-operative radiation dose coverage reported as volumes of prostate receiving a percentage of the prescribed dose, described by mean V100 (% volume)

  5. Dosimetric Coverage of Brachytherapy Implant Described by Mean D90 (% Rx)

    Time frame: Up to 15 days after screening

    Dosimetric coverage of brachytherapy implant described by mean D90 (% Rx), which refers to the main dose in the hottest 90% of the post-implant prostate volume (given as a percent of the RX dose)

  6. Dosimetric Coverage of Targeted Lesion Described by Mean V100 (% Volume)

    Time frame: Up to 15 days after screening

    post-operative radiation dose coverage reported as volumes of targeted lesion receiving a percentage of the prescribed dose, described by mean V100 (% Volume)

  7. Dosimetric Coverage of Targeted Lesion Described by Mean D90 (%Rx)

    Time frame: Up to 15 days after screening

    Dosimetric coverage of target lesion described by mean D90 (% Rx), which refers to the main dose in the hottest 90% of the targeted lesion volume (given as a percent of the RX dose)

Sponsors and collaborators

Lead sponsor

Case Comprehensive Cancer Center

Other

Registry information

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Feb 12, 2016
Registry last updated
Jun 30, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.